All In Biotech

Drug Trial Radar · NCT06425341

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

A Multicenter, Randomized, Open, Parallel-designed Phase II Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 369 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

369

Planned (sponsor's estimate)

Start

Jun 6, 2024

Primary completion

Aug 30, 2026

Study completion Jan 19, 2027

Sponsor

Sponsor type
Industry
First posted
May 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.

Conditions

  • Chronic Hepatitis B

Interventions

  • HRS-5635 InjectionDrug

    HRS-5635 Injection low dose administered by subcutaneous injection

  • HRS-5635 InjectionDrug

    HRS-5635 Injection medium dose administered by subcutaneous injection

  • HRS-5635 InjectionDrug

    HRS-5635 Injection high dose administered by subcutaneous injection

  • HRS-5635 InjectionDrug

    HRS-5635 Injection lowest dose administered by subcutaneous injection

  • HRS-5635 Injection (low dose) and Peg-IFN-αDrug

    HRS-5635 Injection (low dose) and Peg-IFN-α, administered by subcutaneous injection

  • HRS-5635 Injection (high dose) and Peg-IFN-αDrug

    HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection

  • Peg-IFN-αDrug

    Peg-IFN-α, administered by subcutaneous injection

  • HRS-5635 Injection with Peg-IFN-αDrug

    HRS-5635 Injection and Peg-IFN-α, administered by subcutaneous injection

  • HRS-5635 InjectionDrug

    HRS-5635 Injection, administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PartA:Change in mean log10 serum hepatitis B surface antigen levels from baseline at week 12Time frame: Week 12
  2. PartB:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48Time frame: Week 48
  3. PartC:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48Time frame: Week 48
  4. PartD:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48Time frame: Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.